Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Back

Showing results (51-60 of 99) with videos related to

Pageof 10
Sort By:
Antiviral Therapy|April 6, 2012
Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adultsAlessandro Schipani, Deirdre Egan, Laura Dickinson, et al.
Antiviral Therapy|December 15, 2010
Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive menPaul A Randell, Akil G Jackson, Marta Boffito, et al.
The Journal of Antimicrobial Chemotherapy|September 15, 2009
Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytesOmar Janneh, Becky Chandler, Ruben Hartkoorn, et al.
Antiviral Therapy|December 3, 2003
Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytesOmar Janneh, Patrick G Hoggard, John F Tjia, et al.
British Journal of Clinical Pharmacology|September 19, 2002
The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjectsMarta Boffito, Patrick G Hoggard, Helen E Reynolds, et al.
Therapeutic Drug Monitoring|January 30, 2004
Lopinavir protein binding in vivo through the 12-hour dosing intervalMarta Boffito, Patrick G Hoggard, W Edward Lindup, et al.
Antimicrobial Agents and Chemotherapy|December 25, 2002
Enzymatic assay for measurement of intracellular DXG triphosphate concentrations in peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected patientsStephen Kewn, Laurene H Wang, Patrick G Hoggard, et al.
Sexually Transmitted Infections|February 15, 2013
Non-disclosure of HIV status in UK sexual health clinics--a pilot study to identify non-disclosure within a national unlinked anonymous seroprevalence surveyAnn Kathleen Sullivan, Emma J Savage, Catherine M Lowndes, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 13, 2010
Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapyJohn G Evans-Jones, Lucy E Cottle, David J Back, et al.
The Journal of Antimicrobial Chemotherapy|July 16, 2004
Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semenAdil Isaac, Stephen Taylor, Patricia Cane, et al.
Pageof 10

Showing results (51-60 of 99) with videos related to

Sort By:
Pageof 10
Antiviral Therapy|April 6, 2012
Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adultsAlessandro Schipani, Deirdre Egan, Laura Dickinson, et al.
Antiviral Therapy|December 15, 2010
Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive menPaul A Randell, Akil G Jackson, Marta Boffito, et al.
The Journal of Antimicrobial Chemotherapy|September 15, 2009
Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytesOmar Janneh, Becky Chandler, Ruben Hartkoorn, et al.
Antiviral Therapy|December 3, 2003
Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytesOmar Janneh, Patrick G Hoggard, John F Tjia, et al.
British Journal of Clinical Pharmacology|September 19, 2002
The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjectsMarta Boffito, Patrick G Hoggard, Helen E Reynolds, et al.
Therapeutic Drug Monitoring|January 30, 2004
Lopinavir protein binding in vivo through the 12-hour dosing intervalMarta Boffito, Patrick G Hoggard, W Edward Lindup, et al.
Antimicrobial Agents and Chemotherapy|December 25, 2002
Enzymatic assay for measurement of intracellular DXG triphosphate concentrations in peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected patientsStephen Kewn, Laurene H Wang, Patrick G Hoggard, et al.
Sexually Transmitted Infections|February 15, 2013
Non-disclosure of HIV status in UK sexual health clinics--a pilot study to identify non-disclosure within a national unlinked anonymous seroprevalence surveyAnn Kathleen Sullivan, Emma J Savage, Catherine M Lowndes, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 13, 2010
Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapyJohn G Evans-Jones, Lucy E Cottle, David J Back, et al.
The Journal of Antimicrobial Chemotherapy|July 16, 2004
Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semenAdil Isaac, Stephen Taylor, Patricia Cane, et al.
Pageof 10